表紙
市場調查報告書

燒燙傷:開發中產品分析

Burns - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 213115
出版日期 內容資訊 英文 99 Pages
訂單完成後即時交付
價格
Back to Top
燒燙傷:開發中產品分析 Burns - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 99 Pages
簡介

所謂燒燙傷 (燙傷,燒傷) 是指由於熱能和化學藥品,電力,日光,放射性核能等造成人體組織的損傷。主要的症狀有疼痛 (燒燙傷程度愈大疼痛也愈強) ,及皮膚的發炎·腫包,水痘,炭化,變色 (變黑) 等。主要的治療方法有抗生素和止痛藥等。

本報告提供全球各國治療燒燙傷所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

燒燙傷概要

治療藥的開發

  • 燒燙傷開發中產品:概要
  • 燒燙傷開發中產品:比較分析

各企業開發中的的燒燙傷治療藥

大學/研究機關研究中的燒燙傷治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

燒燙傷治療藥:開發中的產品一覽 (各企業)

燒燙傷治療藥:研究中的產品一覽 (各大學/研究機關)

燒燙傷開發治療藥的企業

  • Adocia
  • AlgiPharma AS
  • Amarantus Bioscience Holdings, Inc.
  • American Gene Technologies International Inc.
  • Biogenomics Limited
  • CytoTools AG
  • Destiny Pharma Limited
  • Lakewood-Amedex Inc
  • Madam Therapeutics B.V.
  • MediWound Ltd.
  • Mitochon Pharmaceuticals, Inc.
  • Phosphagenics Limited
  • Se-cure Pharmaceuticals Ltd.
  • Sinclair Pharma Plc
  • Stratatech Corporation
  • Tissue Therapies Limited
  • USV Pvt Ltd

燒燙傷:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

燒燙傷治療藥:開發暫停的產品

燒燙傷治療藥:開發中止的產品

燒燙傷相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11558IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H2 2019, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 4, 2, 17, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Burns - Overview
  • Burns - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Burns - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Burns - Companies Involved in Therapeutics Development
    • Aegle Therapeutics Corp
    • AlgiPharma AS
    • Alliance Pharma Plc
    • Amarantus Bioscience Holdings Inc
    • Anterogen Co Ltd
    • Bioharmony Therapeutics Inc
    • Biomendics LLC
    • CFM Pharma Holding BV
    • Destiny Pharma Plc
    • Energenesis Biomedical Co Ltd
    • FortuneRock (China) Ltd
    • GNT Pharma Co Ltd
    • Hunan Sanqing Pharmaceutical Co Ltd
    • Hypo-Stream Ltd
    • Madam Therapeutics BV
    • Mallinckrodt Plc
    • MediWound Ltd
    • MicroCures Inc
    • NeoMatrix Therapeutics Inc
    • Novion Technologies Inc
    • Phagelux Inc
    • Riptide Bioscience Inc
    • Roji Ltd
    • Se-cure Pharmaceuticals Ltd
    • Shulov Innovative Science Ltd
    • Stemsynergy Therapeutics Inc
    • TGV-Inhalonix Inc
    • Theragnostic Technologies Inc
    • TreeFrog Therapeutics SAS
    • USV Pvt Ltd
    • viDA Therapeutics Inc
    • Washburn Therapeutics Inc
  • Burns - Drug Profiles
    • (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGLE-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aspoxicillin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BH-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Burns and Bone Fractures - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bromelains - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Dermatology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENERGIF-711 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epidermal growth factor biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neu-2000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligomer G for Burn Wounds - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-01SS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Activate FGFR for Cardiovascular, CNS, Dermatology and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pyrvinium pamoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize EPCR for Wounds and Burns - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RNAi Gene therapy to Inhibit FL2 for Erectile Dysfunction, Burns and Ophthalmology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAAP-148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SC-106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SFR-9X0125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • silver sulfadiazine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Burns - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium hypochlorite - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Burns and Dermatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Tolasure - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vanadis-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTI-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XF-70 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZEP-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Burns - Dormant Projects
  • Burns - Discontinued Products
  • Burns - Product Development Milestones
    • Featured News & Press Releases
      • Oct 02, 2019: Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol
      • Sep 24, 2019: Mallinckrodt reports positive burn treatment results
      • Sep 03, 2019: NexoBrid Highlighted in 39 presentations at the 18th European Burns Association Congress in Helsinki
      • Jun 04, 2019: NexoBrid receives Marketing Authorization from Peru's Ministry of Health
      • May 29, 2019: BARDA upsizes support for NexoBrid with an additional $21 million to fund continuous access treatment protocol for thermal burn
      • Apr 24, 2019: Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft Regenerative Skin Tissue in Madison, Wis.
      • Jan 23, 2019: MediWound reports positive top-line data from NexoBrid study
      • Oct 15, 2018: Mallinckrodts Stratatech company awarded $26 million in additional BARDA funding for pediatric studies of stratagraft skin tissue in thermal burns
      • Sep 24, 2018: MediWound awarded additional BARDA contract valued Up to $43 Million for development of NexoBrid for sulfur mustard injuries
      • Sep 05, 2018: NexoBrid receives marketing authorization from Russia's Ministry of Health
      • Jul 18, 2018: U.S. FDA designates Mallinckrodt's StrataGraft as regenerative medicine advanced therapy
      • Jun 19, 2018: MediWound Expands Its NexoBrid Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.
      • Jun 11, 2018: MediWound Completes Enrollment in NexoBrid U.S. Phase 3 DETECT Study
      • Jun 04, 2018: NexoBrid Receives Marketing Authorization From South Koreas Ministry of Health
      • Apr 09, 2018: MediWound's NexoBrid to be Highlighted in Presentations at the American Burn Association 50th Annual Meeting Being Held on April 10-13, 2018 in Chicago
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Burns, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 5: Products under Development by Companies, H2 2019
  • Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 7: Products under Development by Universities/Institutes, H2 2019
  • Table 8: Number of Products by Stage and Target, H2 2019
  • Table 9: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 10: Number of Products by Stage and Route of Administration, H2 2019
  • Table 11: Number of Products by Stage and Molecule Type, H2 2019
  • Table 12: Burns - Pipeline by Aegle Therapeutics Corp, H2 2019
  • Table 13: Burns - Pipeline by AlgiPharma AS, H2 2019
  • Table 14: Burns - Pipeline by Alliance Pharma Plc, H2 2019
  • Table 15: Burns - Pipeline by Amarantus Bioscience Holdings Inc, H2 2019
  • Table 16: Burns - Pipeline by Anterogen Co Ltd, H2 2019
  • Table 17: Burns - Pipeline by Bioharmony Therapeutics Inc, H2 2019
  • Table 18: Burns - Pipeline by Biomendics LLC, H2 2019
  • Table 19: Burns - Pipeline by CFM Pharma Holding BV, H2 2019
  • Table 20: Burns - Pipeline by Destiny Pharma Plc, H2 2019
  • Table 21: Burns - Pipeline by Energenesis Biomedical Co Ltd, H2 2019
  • Table 22: Burns - Pipeline by FortuneRock (China) Ltd, H2 2019
  • Table 23: Burns - Pipeline by GNT Pharma Co Ltd, H2 2019
  • Table 24: Burns - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, H2 2019
  • Table 25: Burns - Pipeline by Hypo-Stream Ltd, H2 2019
  • Table 26: Burns - Pipeline by Madam Therapeutics BV, H2 2019
  • Table 27: Burns - Pipeline by Mallinckrodt Plc, H2 2019
  • Table 28: Burns - Pipeline by MediWound Ltd, H2 2019
  • Table 29: Burns - Pipeline by MicroCures Inc, H2 2019
  • Table 30: Burns - Pipeline by NeoMatrix Therapeutics Inc, H2 2019
  • Table 31: Burns - Pipeline by Novion Technologies Inc, H2 2019
  • Table 32: Burns - Pipeline by Phagelux Inc, H2 2019
  • Table 33: Burns - Pipeline by Riptide Bioscience Inc, H2 2019
  • Table 34: Burns - Pipeline by Roji Ltd, H2 2019
  • Table 35: Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H2 2019
  • Table 36: Burns - Pipeline by Shulov Innovative Science Ltd, H2 2019
  • Table 37: Burns - Pipeline by Stemsynergy Therapeutics Inc, H2 2019
  • Table 38: Burns - Pipeline by TGV-Inhalonix Inc, H2 2019
  • Table 39: Burns - Pipeline by Theragnostic Technologies Inc, H2 2019
  • Table 40: Burns - Pipeline by TreeFrog Therapeutics SAS, H2 2019
  • Table 41: Burns - Pipeline by USV Pvt Ltd, H2 2019
  • Table 42: Burns - Pipeline by viDA Therapeutics Inc, H2 2019
  • Table 43: Burns - Pipeline by Washburn Therapeutics Inc, H2 2019
  • Table 44: Burns - Dormant Projects, H2 2019
  • Table 45: Burns - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Table 46: Burns - Dormant Projects, H2 2019 (Contd..2), H2 2019
  • Table 47: Burns - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Burns, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products by Top 10 Targets, H2 2019
  • Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Routes of Administration, H2 2019
  • Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 9: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 10: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top